---
figid: PMC10377299__cancers-15-03561-g001
figtitle: Development and Role of Capmatinib in the Treatment of MET-Dysregulated
  Non-Small Cell Lung Cancer—A Narrative Review
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC10377299
filename: cancers-15-03561-g001.jpg
figlink: /pmc/articles/PMC10377299/figure/cancers-15-03561-f001/
number: F1
caption: MET signaling pathway and blockade by MET inhibitors. In cancer, the MET
  proto-oncogene is abnormally activated and stimulates other signaling pathways in
  tumor cells, notably PI3K/AKT, JAK/STAT, Ras/MAPK, SRC, and Wnt/beta-catenin [].
  Type 1a inhibitor crizotinib blocks ATP binding to prevent the phosphorylation of
  the receptor, whereas type 1b inhibitors such as capmatinib are more specific and
  bind to a pocket adjacent to the ATP binding site. This figure was generated by
  BioRender.
papertitle: The Development and Role of Capmatinib in the Treatment of MET-Dysregulated
  Non-Small Cell Lung Cancer—A Narrative Review.
reftext: Robert Hsu, et al. Cancers (Basel). 2023 Jul;15(14):3561.
year: '2023'
doi: 10.3390/cancers15143561
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: NSCLC | MET dysregulation | capmatinib | tyrosine kinase inhibitor | detection
automl_pathway: 0.955007
figid_alias: PMC10377299__F1
figtype: Figure
redirect_from: /figures/PMC10377299__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10377299__cancers-15-03561-g001.html
  '@type': Dataset
  description: MET signaling pathway and blockade by MET inhibitors. In cancer, the
    MET proto-oncogene is abnormally activated and stimulates other signaling pathways
    in tumor cells, notably PI3K/AKT, JAK/STAT, Ras/MAPK, SRC, and Wnt/beta-catenin
    []. Type 1a inhibitor crizotinib blocks ATP binding to prevent the phosphorylation
    of the receptor, whereas type 1b inhibitors such as capmatinib are more specific
    and bind to a pocket adjacent to the ATP binding site. This figure was generated
    by BioRender.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - hh
  - ATPsynbeta
  - Atpalpha
  - hop
  - bsk
  - Stat92E
  - MKP-4
  - p38b
  - rl
  - ras
  - Ras64B
  - Ras85D
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - ATP8A2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - KRAS
  - HRAS
  - NRAS
  - Crizotinib
  - ATP
  - Capmatinib
  - Tepotinib
  - Salvolitinib
---
